Prioritising target non-pharmacological interventions for research in Parkinson's disease: Achieving consensus from key stakeholders

被引:9
作者
Bogosian A. [1 ]
Rixon L. [1 ]
Hurt C.S. [1 ]
机构
[1] Division of Health Services Research and Management, City University of London, London
关键词
Intervention development; Parkinson's disease; Public and patient involvement; Research engagement; Research prioritisation; Self-management;
D O I
10.1186/s40900-020-00212-7
中图分类号
学科分类号
摘要
Background: In 2014 Parkinson's UK conducted a research prioritisation exercise with stakeholders highlighting important clinical research questions. The exercise highlighted the need for effective interventions to be developed and tested to tackle a range of non-motor symptoms including: sleep quality, stress and anxiety, mild cognitive impairment, dementia and urinary problems. The present work set out to build on this exercise by prioritising types of non-pharmacological interventions to be tested to treat the identified non-motor symptoms. Methods: A Patient and Public Involvement exercise was used to reach consensus on intervention priorities for the treatment of non-motor symptoms. A Delphi structure was used to support the feedback collected. A first-round prioritisation survey was conducted followed by a panel discussion. Nineteen panellists completed the first-round survey (9 people with Parkinson's and 10 professionals working in Parkinson's) and 16 participated in the panel discussion (8 people with Parkinson's and 8 professionals working in Parkinson's). A second-round prioritization survey was conducted after the panel discussion with 13 people with Parkinson's. Results: Physical activity, third wave cognitive therapies and cognitive training were rated as priority interventions for the treatment of a range of non-motor symptoms. There was broad agreement on intervention priorities between health care professionals and people with Parkinson's. A consensus was reached that research should focus on therapies which could be used to treat several different non-motor symptoms. In the context of increasing digitisation, the need for human interaction as an intervention component was highlighted. Conclusion: Bringing together Parkinson's professionals and people with Parkinson's resulted in a final treatment priority list which should be both feasible to carry out in routine clinical practice and acceptable to both professionals and people with Parkinson's. The workshop further specified research priorities in Parkinson's disease based on the current evidence base, stakeholder preferences, and feasibility. Research should focus on developing and testing non-pharmacological treatments which could be effective across a range of symptoms but specifically focusing on tailored physical activity interventions, cognitive therapies and cognitive training. © 2020 The Author(s).
引用
收藏
相关论文
共 32 条
[1]  
Deane K.H., Flaherty H., Daley D.J., Pascoe R., Penhale B., Clarke C.E., Et al., Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease, BMJ Open, 4, 12, (2014)
[2]  
Krishnan S., Sarma G., Sarma S., Kishore A., Do nonmotor symptoms in Parkinson's disease differ from normal aging?, Mov Disord, 26, 11, pp. 2110-2113, (2011)
[3]  
Hinnell C., Hurt C.S., Landau S., Brown R.G., Samuel M., Nonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?, Mov Disord, 27, 2, pp. 236-241, (2012)
[4]  
Kwok J.Y.Y., Auyeung M., Hyl C., Examining Factors Related to Health-Related Quality of Life in People with Parkinson's Disease, Rehabil Nurs, (2018)
[5]  
Chaudhuri K.R., Healy D.G., Schapira A.H., National Institute for clinical E. non-motor symptoms of Parkinson's disease: Diagnosis and management, Lancet Neurol, 5, 3, pp. 235-245, (2006)
[6]  
Seppi K., Ray Chaudhuri K., Coelho M., Fox S.H., Katzenschlager R., Perez Lloret S., Et al., Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review, Mov Disord, 34, 2, pp. 180-198, (2019)
[7]  
Connolly B., Fox S.H., Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease, Neurotherapeutics., 11, 1, pp. 78-91, (2014)
[8]  
UK Parkinson's Audit - Transforming Care, (2017)
[9]  
Pfeiffer R.F., Management of Autonomic Dysfunction in Parkinson's disease, Semin Neurol, 37, 2, pp. 176-185, (2017)
[10]  
Weintraub D., Morales K.H., Moberg P.J., Bilker W.B., Balderston C., Duda J.E., Et al., Antidepressant studies in Parkinson's disease: A review and meta-analysis, Mov Disord, 20, 9, pp. 1161-1169, (2005)